#QuoinPharmaceuticals (#$QNRX) reported statistically significant interim Netherton Syndrome data, 4/6 patients hit the primary endpoint (p=0.0087), alongside a $50M private placement same morning. Volume: 27M+ shares vs. a 238K average.
prismmarketview.com/quoin-report...
prismmarketview.com/quoin-report...
August 28, 2026 at 4:26 PM
#QuoinPharmaceuticals (#$QNRX) reported statistically significant interim Netherton Syndrome data, 4/6 patients hit the primary endpoint (p=0.0087), alongside a $50M private placement same morning. Volume: 27M+ shares vs. a 238K average.
prismmarketview.com/quoin-report...
prismmarketview.com/quoin-report...
#QNRX Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment
#NethertonSyndrome #QuoinPharmaceuticals
prismmarketview.com/quoin-pharma...
#NethertonSyndrome #QuoinPharmaceuticals
prismmarketview.com/quoin-pharma...
Quoin Pharmaceuticals Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment
The late-stage specialty pharmaceutical company developing treatments for rare and orphan diseases Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), announced a robust
prismmarketview.com
May 13, 2025 at 3:50 PM
#QNRX Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment
#NethertonSyndrome #QuoinPharmaceuticals
prismmarketview.com/quoin-pharma...
#NethertonSyndrome #QuoinPharmaceuticals
prismmarketview.com/quoin-pharma...